Novartis’ experimental multiple sclerosis pill prevented fewer relapses than expected in two late-stage trials, potentially giving its cross-town competitor Roche Holding an advantage with a rival drug it’s developing
DeMonica Amerson's diagnosis of multiple sclerosis in 2001 had been a shock. No one in her family had ever had the autoimmune condition, and it had been difficult to diagnose. Doctors had first thought she had optic neuritis because her symptoms were in her eyes. Then they suspected lupus. After a spinal tap, she was diagnosed with MS.
Christina Applegate said she was misdiagnosed with multiple sclerosis. What happened to her is not as rare as you might think.
Read more in this week’s WSJ Wellness newsletter: 🔗
Novartis peak sales estimates of about $4 billion for its experimental multiple sclerosis pill may be too optimistic, analysts said, after disappointing efficacy results in two late-stage trials
Remember when this was a “conspiracy theory”?
The WHO’s COVID research database lists a paper stating: “COVID-19 vaccination can induce multiple sclerosis via cross-reactive CD4+ T cells that recognize the spike protein of SARS-CoV-2 and myelin peptides.”
In plain English, the proposed mechanism is that the immune system could mistakenly attack myelin, the protective coating around nerves, following vaccination.
This mechanism was being discussed during lockdowns. Critics say concerns like these were dismissed, labelled conspiracy theories, and censored. Now, a paper discussing the potential link appears in a WHO research database.
Parents and the public deserve transparency, honest discussion, and access to the evidence.
Full article: